Biotech Startups

Zilia develops a medical imaging platform that measures biomarkers in the eye to enable early detection of preventable blindness, including glaucoma and diabetic retinopathy. The company leverages spectroscopy and artificial intelligence to provide non-invasive assessment of ocular metabolic activity.

1 investor

ZimVie provides dental implant solutions, including full-arch immediate load implant systems, designed to improve patient smiles, function, and confidence. The company serves dental professionals and patients in Canada.

1 investor

1 investor

ZIÖRA develops fertility technologies for IVF and IUI clinics, including FERTILUX, a patented ex-vivo sperm activation treatment that enhances sperm function to improve embryo quality and pregnancy outcomes in assisted reproductive technology. The company is building a pipeline of reproductive technologies aimed at improving gamete quality and clinic efficiency in the global fertility-care market.</parameter> <parameter name="founders">[]

1 investor

ZModal builds infrastructure and software for real-time, model-driven biomanufacturing processes. The company serves biotech and pharmaceutical manufacturers seeking to optimize regulated production of biologics and living tissues.

1 investor

The Zoetis Foundation is a charitable organization funded by Zoetis Inc. that awards grants to support veterinary professionals and livestock farmers through scholarships, mental health resources, and rural capacity-building programs.

1 investor

ZOLGENSMA is a gene replacement therapy that delivers a working SMN gene to treat spinal muscular atrophy (SMA), a rare genetic disease affecting motor nerve cells. The treatment is designed for infants and children with SMA to help restore survival motor neuron protein production.

1 investor

1 investor

zPREDICTA manufactures three-dimensional tissue culture models derived from patient samples that recreate human organ microenvironments for drug testing. Pharmaceutical companies and researchers use the models to evaluate cancer drug candidates and predict clinical efficacy before human trials.

1 investor

Zura Bio is a clinical-stage biotechnology company developing antibody therapies for autoimmune diseases using a dual antagonism strategy that targets multiple immune pathways simultaneously. Its pipeline includes in-licensed assets such as tibulizumab, crebankitug, and torudokimab, advancing through Phase 2 trials for conditions like systemic sclerosis and hidradenitis suppurativa.

1 investor

Zylem Biosciences develops Metabolic Redox Modulators (MRMs), a patented platform of drug candidates targeting the SR-B1 receptor to treat cancer, cardiovascular disease, and other age-related conditions. The company leverages fifteen years of research from Northwestern University to create therapeutics that induce metabolic dysfunction in disease cells while sparing healthy cells.

1 investor

Zyme Communications provides PR and marketing services to life science companies across Europe and the USA, helping them build visibility with investors, commercial partners, and customers through specialized communications and media outreach.

1 investor

ZZ Biotech develops 3K3A-APC, a genetically engineered variant of human activated protein C (a serine protease) optimized for therapeutic use. The company has agreed in principle to license its 3K3A-APC dermatology program to Dermatherix for wound therapy applications.

1 investor

GREEN VET is a pet healthcare diagnostics and services company providing diagnostic testing, health screening, and veterinary care solutions to veterinarians in South Korea. Founded as part of the GC group, it operates as a total animal healthcare provider serving the domestic veterinary industry.

1 investor

NeoCannBio is a technology spin-off from KIST developing cannabinoid-based pharmaceuticals and producing hemp-derived cannabinoid drug ingredients, including high-purity CBD via microwave processing and GMP production. The company builds a broad cannabinoid library and develops new drugs for patients with rare and intractable diseases in Korea.

1 investor

Novelty Nobility develops antibody and protein therapeutics for clinical applications. The company's leadership team brings expertise in immunization, affinity maturation, and biopharmaceutical development across therapeutic areas including ophthalmology.

1 investor

Novorex is a drug discovery company that combines AI, fragment-based drug discovery (FBDD), and biophysical validation (SPR, NMR, X-ray crystallography, and wet-lab assays) to develop novel small-molecule therapeutics. It operates in-house CNS and inflammation pipelines with R&D labs in Pangyo, Central, and Jeongeup.

1 investor

NeuroVenti is a biotech company developing neuroprotective and therapeutic agents for neuronal and central nervous system disorders, including a drug candidate (NV01-A02) for autism spectrum disorder currently in domestic Phase 2 clinical trials. It also offers preclinical CDRO services such as candidate discovery, preclinical research consulting, and efficacy and safety evaluation.

1 investor

Deep Bio is a medical AI company that develops cancer diagnostic software using deep learning technology. The company conducts clinical trials on its medical devices and plans to commercialize products in domestic and international biotech markets.

1 investor

Renhaim is a biotechnology company developing advanced RNA-based pharmaceuticals, including cancer therapeutics, preventive vaccines, and gene/cell therapies for unmet medical needs.

1 investor

LigaChemBio is a biotechnology company focused on drug development, particularly in ADC (antibody-drug conjugate) and small molecule therapeutics. The company develops and partners on therapeutic pipelines for pharmaceutical applications.

1 investor

MicrobiotiX develops bacteriophage-based therapeutics targeting multi-drug resistant bacterial infections, including WHO/CDC priority pathogens such as Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and E. coli. The company operates a phage discovery and development platform with a library of about 1,000 bacteriophages, in-silico modules, and GMP production facilities, and its lead pipeline MP101 has entered clinical trials with first-patient-in completed.

1 investor

MEPSGEN develops microphysiological systems (MPS) and organ-on-chip technologies for drug development and testing, serving pharmaceutical companies and contract research organizations. The company manufactures nanoparticles and microspheres, produces automated robotic systems for MPS modeling, and develops nanomedicines for diseases including glioblastoma and Alzheimer's disease.

1 investor

Based on the partner page listing major Korean hospitals, pharmaceutical firms, and international biotech institutions, the company appears to operate in healthcare or biotech, but the page does not explicitly state the company's core business or customer focus.

1 investor